1. Home
  2. Analysis
  3. Neulasta
  4. Ribasphere

Neulasta and Ribasphere drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Neulasta (pegfilgrastim) and Ribasphere (ribavirin). Common drug interactions include nasopharyngitis among females and anxiety among males.

The phase IV clinical study analyzes what interactions people have when they take Neulasta and Ribasphere. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Neulasta?

Neulasta has active ingredients of pegfilgrastim. It is often used in agranulocytosis. eHealthMe is studying from 92,286 Neulasta users. Check the latest studies of Neulasta.

What is Ribasphere?

Ribasphere has active ingredients of ribavirin. It is often used in hepatitis c. eHealthMe is studying from 9,336 Ribasphere users. Check the latest studies of Ribasphere.

On Jul, 26, 2026

11 people who take Neulasta and Ribasphere together, and have interactions are studied.

Neulasta and Ribasphere drug interactions.

What are the common drug interactions of Neulasta and Ribasphere, by gender? *:

female:

  1. Nasopharyngitis (inflammation of the nasopharynx)
  2. Nausea (feeling of having an urge to vomit)
  3. Oropharyngeal pain
  4. Vomiting
  5. White blood cell count decreased
  6. Contusion (a type of hematoma of tissue in which capillaries)
  7. Decreased appetite
  8. Diarrhoea
  9. Facial palsy (paralysis of face nerve)
  10. Fall

male:

  1. Anxiety
  2. Formication (a sensation that exactly resembles that of small insects crawling on (or under) the skin)
  3. Muscular weakness (muscle weakness)
  4. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  5. Tremor (trembling or shaking movements in one or more parts of your body)

What are the common drug interactions of Neulasta and Ribasphere, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Depression
  2. Dizziness
  3. Contusion (a type of hematoma of tissue in which capillaries)
  4. Decreased appetite
  5. Diarrhoea
  6. Facial palsy (paralysis of face nerve)
  7. Fall
  8. Head injury
  9. Limb injury
  10. Weight decreased

60+:

n/a

What are the existing conditions these people have? *

  1. Neuromyelitis Optica (inflammation and demyelination of the optic nerve (optic neuritis) and the spinal cord (myelitis)): 1 person, 9.09%
  2. Demyelination (loss of the myelin covering of some nerve fibres resulting in their impaired function): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Neulasta and Ribasphere?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Neulasta and Ribasphere:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Neulasta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ribasphere:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Neulasta and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ribasphere and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on pegfilgrastim and ribavirin (the active ingredients of Neulasta and Ribasphere, respectively), and Neulasta and Ribasphere (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.